Hirudin anticoagulation allows more rapid determination of P2Y12 inhibition by the VerifyNow P2Y12 assay

Thrombosis and Haemostasis

Volumn 109, Issue 3, 2013, Pages 550-555

  Sumaya, Wael ^a   Daly, Rebecca L ^a   Mehra, Sonal ^a   Dhutia, Amrita J ^a   Howgego, Kate E ^a   Ecob, Rosemary ^a   Judge, Heather M ^a   Morton, Allison C ^a   Storey, Robert F ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Citrate; Hirudin; Myocardial infarction; P2Y12; PCI; VerifyNow

Indexed keywords

ACETYLSALICYLIC ACID; CITRATE SODIUM; CLOPIDOGREL; HIRUDIN; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; THROMBIN RECEPTOR ACTIVATING PEPTIDE; TROPONIN;

ADULT; ANGIOCARDIOGRAPHY; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING PARAMETERS; CORONARY ARTERY DISEASE; FEMALE; FLOW CYTOMETRY; HEART INFARCTION; HUMAN; LIGHT TRANSMISSION AGGREGOMETRY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION;

ACUTE CORONARY SYNDROME; AGED; ANTICOAGULANTS; ANTITHROMBINS; AREA UNDER CURVE; CATIONS; CITRATES; CORONARY ANGIOGRAPHY; FEMALE; HEMATOLOGIC TESTS; HIRUDINS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PIPERAZINES; PLATELET FUNCTION TESTS; RECEPTORS, PURINERGIC P2Y12; THIOPHENES; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84874759680     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-10-0718     Document Type: Article

References (15)

1. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011; 124: 2574-2609.
2. Cattaneo M, Podda GM. State of the art of new P2Y12 antagonists. Int Emerg Med 2010; 5: 385-391.
3. Gurbel PA, Tantry US. Clopidogrel resistance? Thromb Res 2007; 120: 311-321.
4. Barragan P, Bouvier JL, Roquebert PO, et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilatorstimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 2003; 59: 295-302.
5. Grove EL, Storey RF, Wurtz M. Platelet function testing in atherothrombotic disease. Curr Pharm Des 2012; Epub ahead of print.
6. Malinin A, Pokov A, Swaim L, et al. Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel. Meth Find Exp Clin Pharmacol 2006; 28: 315-322.
7. Pittens CA, Bouman HJ, van Werkum JW, et al. Comparison between hirudin and citrate in monitoring the inhibitory effects of P2Y12 receptor antagonists with different platelet function tests. Journal of thrombosis and haemostasis: J Thromb Haemost 2009; 7: 1929-1932.
8. Judge HM, Buckland RJ, Sugidachi A, et al. Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function. Thromb Haemost 2010; 103: 1210-1217.
9. Brar SS, ten Berg J, Marcucci R, et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol 2011; 58: 1945-1954.
10. Kaiser AF, Neubauer H, Franken CC, et al. Which is the best anticoagulant for whole blood aggregometry platelet function testing? Comparison of six anticoagulants and diverse storage conditions. Platelets 2012; 23: 359-367.
11. Zhang HZ, Yu LH, Kim MH. Effect of different anticoagulants on multiple electrode platelet aggregometry after clopidogrel and aspirin administration in patients undergoing coronary stent implantation: A comparison between citrate and hirudin. Platelets 2012; Epub ahead of print.
12. Kalb ML, Potura L, Scharbert G, et al. The effect of ex vivo anticoagulants on whole blood platelet aggregation. Platelets 2009; 20: 7-11.
13. Lansky AJ, Stone GW. Periprocedural myocardial infarction: prevalence, prognosis, and prevention. Circ Cardiovasc Interv 2010; 3: 602-610.
14. Mangiacapra F, Patti G, Barbato E, et al. A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study. JACC 2012; 5: 281-289.
15. Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 919-933.